Visiongain states that ‘Global Generic Drugs Market Set To Grow To $423.7bn By 2023’

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico

The generic drugs market has historically increased at near double-digit growth rates over the last three decades, compared to single-digit growth for the pharmaceutical market as a whole. The industry has benefited from increasing generic penetration in most major markets notable exceptions being Japan, France, Italy and Spain, where generic penetration is increasing slowly. This trend is likely to continue as falling R&D productivity begins to limit revenues for innovator companies while cost pressures encourage the growth of generic sales by volume.

The lead analyst of the report commented “The socio-economic landscape of many national and regional markets globally has been changing immensely over the last decade. This factor, coupled with the changing in the demographics of these regions will help to shape the future direction of generic drugs over the next 10 years. Population growth and ageing are expected to increase the burden of disease, especially chronic diseases such as diabetes and hypertension. This will be a major driver of the demand for generic medicines during the forecast period.”

Leading companies featured in the report include Teva, Novartis (Sandoz), Allergan, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories, Apotex

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever